Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain
- PMID: 8315392
- PMCID: PMC2191075
- DOI: 10.1084/jem.178.1.361
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain
Abstract
To expand the spectrum of recognition of effector lymphocytes and to redirect them towards predefined targets, we have altered the specificity of human tumor-infiltrating lymphocytes (TIL) through stable modification with chimeric receptor genes consisting of single-chain antibody variable regions linked to the gamma subunit common to the immunoglobulin (Ig)G and IgE Fc receptors. Using either hapten or ovarian carcinoma-specific monoclonal antibodies, we constructed chimeric receptor genes and retrovirally introduced them into CD8+ TIL. Redirected TIL specifically lysed trinitrophenyl-labeled Daudi or a human ovarian carcinoma cell line (IGROV-1), and secreted granulocyte/macrophage colony-stimulating factor upon stimulation with the appropriate antigen. This strategy may allow new approaches towards the adoptive immunotherapy of cancer in humans.
Similar articles
-
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.Cancer Res. 1995 Aug 1;55(15):3369-73. Cancer Res. 1995. PMID: 7614473
-
Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.Eur J Immunol. 1998 May;28(5):1663-72. doi: 10.1002/(SICI)1521-4141(199805)28:05<1663::AID-IMMU1663>3.0.CO;2-L. Eur J Immunol. 1998. PMID: 9603473
-
T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.J Immunol. 1993 Nov 15;151(10):5472-80. J Immunol. 1993. PMID: 8228239
-
The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.Cancer Detect Prev. 1994;18(1):43-50. Cancer Detect Prev. 1994. PMID: 8162605 Review.
-
Novel immunologic strategies in ovarian carcinoma.Am J Obstet Gynecol. 1992 Nov;167(5):1470-8. doi: 10.1016/s0002-9378(11)91735-9. Am J Obstet Gynecol. 1992. PMID: 1332480 Review.
Cited by
-
Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.Neoplasia. 2000 Sep-Oct;2(5):449-59. doi: 10.1038/sj.neo.7900108. Neoplasia. 2000. PMID: 11191112 Free PMC article.
-
Bringing cell therapy to tumors: considerations for optimal CAR binder design.Antib Ther. 2023 Sep 12;6(4):225-239. doi: 10.1093/abt/tbad019. eCollection 2023 Oct. Antib Ther. 2023. PMID: 37846297 Free PMC article. Review.
-
The immunobiological effects of interleukin-2 in vivo.Cancer Immunol Immunother. 1994 Oct;39(4):207-16. doi: 10.1007/BF01525983. Cancer Immunol Immunother. 1994. PMID: 7954522 Free PMC article. Review. No abstract available.
-
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15. doi: 10.1158/1078-0432.CCR-06-1183. Clin Cancer Res. 2006. PMID: 17062687 Free PMC article. Clinical Trial.
-
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.J Immunother. 2009 Sep;32(7):689-702. doi: 10.1097/CJI.0b013e3181ac6138. J Immunother. 2009. PMID: 19561539 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials